Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Everest Approved to Launch Antibiotic in China for Intra-Abdominal Infections

publication date: Mar 16, 2023

Shanghai Everest Medicines announced Xerava® (eravacycline) was approved in China to treat complicated intra-abdominal infections in adult patients. Xerava, which will be Everest’s first commercialized drug, is a novel parenteral broad-spectrum, fluorocycline antibiotic of the tetracycline class. It has shown broad in vitro activity against Gram-negative and Gram-positive pathogens with multidrug resistance. In 2018, Everest in-licensed Greater China rights for Xerava from Boston’s Tetraphase Pharma in a $43 million agreement. Xerava is already approved in the US, EU and other parts of the world. More details....

Stock Symbol: (HK 1952)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital